Hyperprogressive disease in patients with non‐small cell lung cancer treated with nivolumab: A case series

Nivolumab is an anti‐PD‐1 blocking monoclonal antibody approved for the treatment of non‐small cell lung cancer (NSCLC). However, some patients on immunotherapy may experience rapid progression and worsening clinical status, known as hyperprogressive disease. We retrospectively reviewed the clinical...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Thorac Cancer
Principais autores: Kanazu, Masaki, Edahiro, Ryuya, Krebe, Hiroyuki, Nishida, Kohei, Ishijima, Mikako, Uenami, Takeshi, Akazawa, Yuki, Yano, Yukihiro, Yamaguchi, Toshihiko, Mori, Masahide
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons Australia, Ltd 2018
Assuntos:
Case Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6275832/
https://ncbi.nlm.nih.gov/pubmed/30328672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12894
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados